Ocular Therapeutix Inc.

OCUL

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

Avoro Capital Advisors Rock Springs Capital OrbiMed Advisors

Position Trend

Feb 17, 2026

$6.1M

2 funds

Mar 16, 2026

$130.8M

1 fund

+2042% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Avoro Capital AdvisorsNEWMar 16, 2026

Shares: 10,777,777Value: $130.8M

**Signal Note: Avoro Capital Initiates $130.8M Position in OCUL** Avoro's entry at scale suggests conviction in Ocular Therapeutix's pipeline, likely anchored on OTX-TIC (travoprost intracanalicular insert) for glaucoma—a sustained-release candidate addressing the $7B+ glaucoma market with potential for improved compliance versus daily drops. Key near-term catalysts include topline Phase 3 data and regulatory feedback, which could de-risk a differentiated mechanism targeting a massive patient base with high treatment discontinuation rates.

Rock Springs CapitalNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

APLS3 funds ARGX3 funds ASND3 funds PTCT3 funds GPCR3 funds VERA3 funds XENE3 funds RVMD

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

**SIGNAL NOTE: Rock Springs Capital initiates $4.2M position in OCUL** Rock Springs' entry suggests conviction in Ocular Therapeutix's pipeline, likely centered on sustained-release eye drop candidates (ReSure, dexamethasone implant) addressing dry eye and post-operative inflammation—markets with limited differentiated therapies. The initiation by a healthcare specialist concentrated fund warrants monitoring for upcoming catalysts: Phase 3 readouts, FDA decisions, or commercial traction data that could validate the sustained-release platform versus standard formulations.